tiprankstipranks
Trending News
More News >
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Australian Market
Advertisement

Chimeric Therapeutics Ltd. (CHM) Stock Statistics & Valuation Metrics

Compare
12 Followers

Total Valuation

Chimeric Therapeutics Ltd. has a market cap or net worth of AU$10.93M. The enterprise value is AU$2.30M.
Market CapAU$10.93M
Enterprise ValueAU$2.30M

Share Statistics

Chimeric Therapeutics Ltd. has 3,642,136,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,642,136,200
Owned by Insiders
Owned by Institutions

Financial Efficiency

Chimeric Therapeutics Ltd.’s return on equity (ROE) is -5.28 and return on invested capital (ROIC) is -219.52%.
Return on Equity (ROE)-5.28
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-219.52%
Return on Capital Employed (ROCE)-2.17
Revenue Per Employee
Profits Per Employee
Employee Count
Asset Turnover0.18
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Chimeric Therapeutics Ltd. is ―. Chimeric Therapeutics Ltd.’s PEG ratio is 0.00906.
PE Ratio
PS Ratio1.36
PB Ratio2.74
Price to Fair Value2.74
Price to FCF-0.74
Price to Operating Cash Flow-1.02
PEG Ratio0.00906

Income Statement

In the last 12 months, Chimeric Therapeutics Ltd. had revenue of 3.97M and earned -10.43M in profits. Earnings per share was -0.01.
Revenue3.97M
Gross Profit3.12M
Operating Income-15.11M
Pretax Income-10.32M
Net Income-10.43M
EBITDA-9.08M
Earnings Per Share (EPS)-0.01

Cash Flow

In the last 12 months, operating cash flow was -4.96M and capital expenditures 0.00, giving a free cash flow of -4.96M billion.
Operating Cash Flow-4.96M
Free Cash Flow-4.96M
Free Cash Flow per Share>-0.01

Dividends & Yields

Chimeric Therapeutics Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.61
52-Week Price Change0.00%
50-Day Moving Average
200-Day Moving Average
Relative Strength Index (RSI)
Average Volume (3m)3.63M

Important Dates

Chimeric Therapeutics Ltd. upcoming earnings date is Feb 26, 2026, Before Open (Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date

Financial Position

Chimeric Therapeutics Ltd. as a current ratio of 0.72, with Debt / Equity ratio of 0.00%
Current Ratio0.72
Quick Ratio0.72
Debt to Market Cap0.00
Net Debt to EBITDA0.63
Interest Coverage Ratio-71.61

Taxes

In the past 12 months, Chimeric Therapeutics Ltd. has paid 110.81K in taxes.
Income Tax110.81K
Effective Tax Rate-0.01

Enterprise Valuation

Chimeric Therapeutics Ltd. EV to EBITDA ratio is 0.04, with an EV/FCF ratio of 0.05.
EV to Sales-0.09
EV to EBITDA0.04
EV to Free Cash Flow0.05
EV to Operating Cash Flow0.05

Balance Sheet

Chimeric Therapeutics Ltd. has AU$5.76M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$5.76M billion.
Cash & Marketable SecuritiesAU$5.76M
Total DebtAU$0.00
Net CashAU$5.76M
Net Cash Per Share<AU$0.01
Tangible Book Value Per Share>-AU$0.01

Margins

Gross margin is 95.36%, with operating margin of -380.78%, and net profit margin of -262.83%.
Gross Margin95.36%
Operating Margin-380.78%
Pretax Margin-260.04%
Net Profit Margin-262.83%
EBITDA Margin-228.71%
EBIT Margin-254.72%

Analyst Forecast

The average price target for Chimeric Therapeutics Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast46.28%

Scores

Smart Score2
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis